pISSN 1226-6051
eISSN 2508-786X
eISSN 2508-786X
Characteristics of included studies
| Study name | Study design | Sample size | Intervention fluids | Gender Male (%) | median Age (years) Intervention vs Control | Diagnosis | Disease severity assessment Intervention vs Control | MV (%) Intervention vs Control |
|---|---|---|---|---|---|---|---|---|
| Wu BU 201142) | Randomized controlled study | 40 | LR | 55.0 | 50(40-73) vs 54(40-60) | Acute pancreatitis | SIRS: 32% vs 19% BISAP : 0 vs 1 median APACHE II: 3 vs 3 | NA |
| Young P 201544) | Double-blind, cluster randomized, double-crossover trial | 2,262 | PL 148 | 65.6 | 60.10(16.79) vs 60.95(16.25) | Sepsis, Trauma, Brain Injury, Operative admission (ICU) | mean APACHE II: 14.1 vs 14.1 | 67.0% vs 66.0% |
| Verma B 201641) | Randomized controlled pilot study | 67 | PL 148 | 62.7 | 62(45-70) vs 64(46-72) | Sepsis,Trauma, Operative admission (ICU) | median APACHE III: 55 vs 64 Vasopressor use: 45.5% vs 32.4% | 57.6% vs 55.9% |
| Semler MW 201739) | Cluster-randomized, multiple-crossover trial | 974 | LR PL 148 | 52.8 | 57(44-68) vs 58(46-70) | Sepsis, Pneumonia, Respiratory failure, GI bleeding, Liver failure, Ingestion, Malignancy, DKA, AKI (ICU) | Vasopressor use: 21.9 % vs 24.4 % Stage 2 AKI 18.5% vs 19.2% | 33.5% vs 34.1 % |
| Semler MW 201813) | Randomized controlled study | 15,802 | LR PL 148 | 57.6 | 58(44-69) vs 58(44-69) | Sepsis,Trauma, Brain Injury (ICU) | Vasopressor use: 26.4 % vs 26.2 % Stage 2 AKI 8.6% vs 8.2% | 34.3% vs 34.7 % |
| de-Madaria E 201814) | Randomized controlled study | 40 | LR | 47.5 | 61.4(15.5) |
Acute pancreatitis | SIRS criteria ≥ 2 47.4 % vs 66.7% | NA |
| Golla R 202040) | Open label RCT | 160 | LR | 53.1 | 43.46(17.99) |
Sepsis (ED) | mean SOFA: 7.63 vs 7.64 | NA |
| Jackson KE 202146) | Secondary analysis of SMART trial (Semler MW, 2018) | 1,641 | LR PL 148 | 54.7 | 59 (45-69) vs 59 (46-69) | Sepsis (ICU) | Vasopressor use: 41.9% vs 40.4% Stage 2 AKI 25.1% vs 25.5% | 39.3% vs 40.8% |
| Raghunathan K 201429) | Cohort study | 6,730 | LR Normosol PL 148 | 48.5 | 64(53-77) vs 64(52-76) | Sepsis (ICU) | Renal failure: 20.8 % vs 20.5% | 44.7% vs 43.3% |
| Duffy RA 2019 15) | Cohort study | 1,218 | Normosol | 47.7 | 60.6(18.7) |
Sepsis (ED) | mean qSOFA: 0.70 vs 0.68 | NA |
| Shaw AD 201545) | Cohort study | 3,116 | Normosol PL 148 | 42.8 | NA | SIRS (SIRS criteria) | SIRS: 100 % of total population | NA |
| Lipinski M 201516) | Cohort study | 103 | LR | 66.0 | 49.2(18.0) |
Acute pancreatitis | BISAP ≥ 3: 20.0% vs 12.7% | NA |
| Aboelsoud MM 201643) | Cohort study | 198 | LR | 50.3 | 63(52-74) |
Acute pancreatitis (ICU) | BISAP ≥ 3: 32.3% vs 26.9% |
NA |
AKI=acute kidney injury, AP=acute pancreatitis, APACHE=Acute Physiology and Chronic Health Evaluation, BISAP=Bedside index of severity in acute pancreatitis, DKA=diabetic ketoacidosis, ED=emergency department, GI=gastrointestinal, ICU=intensive care unit, LR=Lactated Ringer’s solution, MV=mechanical ventilator, NA=not available, PL 148=Plasma-Lyte 148, SAPS=Simplified Acute Physiology Score, SIRS=systemic inflammatory response syndrome, SOFA=sequential organ failure assessment
*